Cargando…

Regulation of PD-L1 Expression by Nuclear Receptors

The suppression of excessive immune responses is necessary to prevent injury to the body, but it also allows cancer cells to escape immune responses and proliferate. Programmed cell death 1 (PD-1) is a co-inhibitory molecule that is present on T cells and is the receptor for programmed cell death li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kiriyama, Yoshimitsu, Nochi, Hiromi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298609/ https://www.ncbi.nlm.nih.gov/pubmed/37373038 http://dx.doi.org/10.3390/ijms24129891

Ejemplares similares

Role of Microbiota-Modified Bile Acids in the Regulation of Intracellular Organelles and Neurodegenerative Diseases
por: Kiriyama, Yoshimitsu, et al.
Publicado: (2023)

The Role of Gut Microbiota-Derived Lithocholic Acid, Deoxycholic Acid and Their Derivatives on the Function and Differentiation of Immune Cells
por: Kiriyama, Yoshimitsu, et al.
Publicado: (2023)

The Function of Autophagy in Neurodegenerative Diseases
por: Kiriyama, Yoshimitsu, et al.
Publicado: (2015)

Role and Cytotoxicity of Amylin and Protection of Pancreatic Islet β-Cells from Amylin Cytotoxicity
por: Kiriyama, Yoshimitsu, et al.
Publicado: (2018)

Intra- and Intercellular Quality Control Mechanisms of Mitochondria
por: Kiriyama, Yoshimitsu, et al.
Publicado: (2017)

The Biosynthesis, Signaling, and Neurological Functions of Bile Acids
por: Kiriyama, Yoshimitsu, et al.
Publicado: (2019)

Physiological Role of Bile Acids Modified by the Gut Microbiome
por: Kiriyama, Yoshimitsu, et al.
Publicado: (2021)

D-Amino Acids in the Nervous and Endocrine Systems
por: Kiriyama, Yoshimitsu, et al.
Publicado: (2016)

PD-L1: expression regulation
por: Zhou, Yu-Jie, et al.
Publicado: (2023)

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
por: Garcia-Diaz, Angel, et al.
Publicado: (2017)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Regulation of PD-L1 expression in the tumor microenvironment
por: Yi, Ming, et al.
Publicado: (2021)

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
por: Wang, Qingshui, et al.
Publicado: (2017)

Regulation of sister chromatid cohesion by nuclear PD-L1
por: Yu, Jia, et al.
Publicado: (2020)

The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation
por: Fan, Zhiwei, et al.
Publicado: (2022)

Role of regulation of PD-1 and PD-L1 expression in sepsis
por: Zhang, Teng, et al.
Publicado: (2023)

PD-L1 Expression in Mastocytosis
por: Williams, Margaret, et al.
Publicado: (2019)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
por: Gao, Yang, et al.
Publicado: (2020)

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
por: Broos, Katrijn, et al.
Publicado: (2018)

Author Correction: Regulation of sister chromatid cohesion by nuclear PD-L1
por: Yu, Jia, et al.
Publicado: (2020)

Glial Cell Expression of PD-L1
por: Chauhan, Priyanka, et al.
Publicado: (2019)

Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2023)

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
por: Rotman, Jossie, et al.
Publicado: (2020)

Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma
por: Yokoyama, Shintaro, et al.
Publicado: (2020)

Current insight into the regulation of PD-L1 in cancer
por: Liu, Zhuandi, et al.
Publicado: (2022)

Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma
por: Smithy, James W., et al.
Publicado: (2017)

PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies
por: Mucileanu, Adrian, et al.
Publicado: (2021)

GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors
por: Fu, Yujie, et al.
Publicado: (2020)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Searching for the real function of mTOR signaling in the regulation of PD-L1 expression
por: Sun, Shi-Yong
Publicado: (2020)

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
por: Šmahel, Michal
Publicado: (2017)

CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers
por: Gao, Feng, et al.
Publicado: (2019)

Regulation of PD-L1 Trafficking from Synthesis to Degradation
por: Lemma, Eyoel Yemanaberhan, et al.
Publicado: (2023)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

γH2AX, a DNA Double-Strand Break Marker, Correlates with PD-L1 Expression in Smoking-Related Lung Adenocarcinoma
por: Sakurai, Eiko, et al.
Publicado: (2022)

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
por: Klepsch, Victoria, et al.
Publicado: (2018)

Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
por: Wang, Tao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_415gspr2dfu1aj5u0f4ip9r5mp